William J. Sandborn
Expertise in
15
conditions

Dr. William J. Sandborn

Gastroenterology
UC San Diego Student Health SVC Pharmacy
9500 Gilman Dr, 
La Jolla, CA 
Accepting New Patients
Referral may be required
Before you request
Expertise in
15
conditions
UC San Diego Student Health SVC Pharmacy
9500 Gilman Dr, 
La Jolla, CA 

Overview

William Sandborn is a Gastroenterologist practicing medicine in La Jolla, California.

Dr. Sandborn is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Hemorrhagic Proctocolitis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

He is actively involved in clinical research, co-authoring 571 peer reviewed articles and participating in 12 clinical trials. Dr. Sandborn is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UC San Diego Student Health SVC Pharmacy
9500 Gilman Dr, La Jolla, CA 92093

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
Enrollment Status: Active_not_recruiting
Publish Date: June 02, 2026
Intervention Type: Drug
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: September 05, 2023
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
Enrollment Status: Terminated
Publish Date: January 04, 2022
Intervention Type: Drug
A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis
A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

571 Total Publications

Comparative genomic analysis of Bacteroides fragilis from intestinal and extra-intestinal sites.
Comparative genomic analysis of Bacteroides fragilis from intestinal and extra-intestinal sites.
Journal: Microbiology spectrum
Published: July 14, 2026
Similar Doctors
Expertise in
13
conditions
Dr. Rena H. Yadlapati
Gastroenterology
Expertise in
13
conditions
Dr. Rena H. Yadlapati
Gastroenterology
Referral may be required

UC San Diego Health Clinical Laboratory-La Jolla

9350 Campus Point Dr, 
La Jolla, CA 
 (0.6 miles away)
619-543-2347
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rena Yadlapati is a Gastroenterologist practicing medicine in La Jolla, California. Dr. Yadlapati is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Achalasia, Heartburn, Endoscopy, and Colonoscopy.

Expertise in
9
conditions
Dr. Ravinder K. Mittal
Gastroenterology
Expertise in
9
conditions
Dr. Ravinder K. Mittal
Gastroenterology
Referral may be required

UC San Diego Health Clinical Laboratory-La Jolla

9350 Campus Point Dr, 
La Jolla, CA 
 (0.6 miles away)
619-543-6834
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravinder Mittal is a Gastroenterologist practicing medicine in La Jolla, California. Dr. Mittal is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Achalasia, Bowel Incontinence, Swallowing Difficulty, Gastroesophageal Reflux Disease (GERD), and Sleeve Gastrectomy.

Expertise in
16
conditions
Dr. Paul J. Pockros
Gastroenterology
Expertise in
16
conditions
Dr. Paul J. Pockros
Gastroenterology
Referral may be required

Scripps Green Hospital

10666 N Torrey Pines Rd, 
La Jolla, CA 
 (1.6 miles away)
858-295-3054
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Paul Pockros is a Gastroenterologist practicing medicine in La Jolla, California. Dr. Pockros is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Hepatitis, Primary Biliary Cholangitis, Cirrhosis, and Hepatitis C.

Frequently Asked Questions about Dr. William J. Sandborn

How do I make an appointment with Dr. William J. Sandborn?

You can book an appointment with Dr. William J. Sandborn by calling their office at 858-657-6327. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. William J. Sandborn a top-rated expert for Crohn's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. William J. Sandborn is classified as an Elite expert for Crohn's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. William J. Sandborn specialize in?

While Dr. William J. Sandborn is a Gastroenterology, they have specific expertise in Crohn's Disease, Hemorrhagic Proctocolitis, and Ulcerative Colitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. William J. Sandborn participate in research or clinical trials?

Yes. Dr. William J. Sandborn has published 571 articles and abstracts on conditions like Crohn's Disease. You can view a list of Dr. William J. Sandborn's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. William J. Sandborn accept my insurance?

Dr. William J. Sandborn accepts most major insurance plans, including Humana. We recommend calling the office directly at 858-657-6327 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sandborn's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 7 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile